Bioavailability Prediction Based on Molecular Structure for a Diverse Series of Drugs

Pharmaceutical Research

Volumn 21, Issue 1, 2004, Pages 68-82

  Turner, Joseph V ^a   Maddalena, Desmond J ^b   Agatonovic Kustrin, Snezana ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Absorption; QSPkR; Quantitative structure property relationship; RBF ANN; Theoretical descriptors

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ALENDRONIC ACID; ALLOPURINOL; AMANTADINE; AMILORIDE; AMINOGLUTETHIMIDE; AMIODARONE; AMITRIPTYLINE; AMLODIPINE; AMOXICILLIN; AMPICILLIN; ATENOLOL; ATORVASTATIN; ATROPINE; AZATHIOPRINE; BACLOFEN; BENDROFLUMETHIAZIDE; BETAMETHASONE; BROMOCRIPTINE; BUMETANIDE; CAPTOPRIL; CARBAMAZEPINE; CEFALEXIN; CHLORAMPHENICOL; CHLORDIAZEPOXIDE; CHLOROTHIAZIDE; CHLORTALIDONE; CIMETIDINE; UNINDEXED DRUG;

ARTICLE; ARTIFICIAL NEURAL NETWORK; CORRELATION COEFFICIENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE PROPERTY RELATION; THEORETICAL MODEL;

ANALYSIS OF VARIANCE; BIOLOGICAL AVAILABILITY; COMPUTATIONAL BIOLOGY; DATA INTERPRETATION, STATISTICAL; HUMANS; MOLECULAR STRUCTURE; NEURAL NETWORKS (COMPUTER); PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 1642579654     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000012154.09631.26     Document Type: Article

References (249)

1. G. L. Amidon, P. J. Sinko, and D. Fleisher. Estimating human oral fraction dose absorbed a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res. 5:651-654 (1988).
2. M. D. Wessel, P. C. Jurs, J. W. Tolan, and S. M. Muskal. Prediction of human intestinal absorption of drug compounds from molecular structure. J. Chem. Inf. Comput. Sci. 38:726-735 (1998).
3. F. Yoshida and J. G. Topliss. QSAR model for drug human oral bioavailability. J. Med. Chem. 43:2575-2585 (2000).
4. C. W. Andrews, L. Bennett, and L. X. Yu. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharm. Res. 17:639-644 (2000).
5. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26 (2001).
6. A. T. Balaban and J. Devillers. Topological Indices and Related Descriptors in QSAR and QSPR, Gordon & Breach, Amsterdam, 1999.
7. A. Bras, D. Sitar, and F. Aoki. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. Can. J. Clin. Pharmacol. 8:207-211 (2001).
8. B. J. Gertz, S. H. Holland, W. F. Kline, B. K. Matuszewski, A. Freeman, H. Quan, K. C. Lasseter, J. C. Mucklow, and A. G. Porras. Studies of the oral bioavailability of alendronate. Clin. Pharmacol. Ther. 58:288-298 (1995).
9. S. J. Appelbaum, M. Mayersohn, R. T. Dorr, and D. Perrier. Allopurinol kinetics and bioavailability. Intravenous oral and rectal administration. Cancer Chemother. Pharmacol. 8:93-98 (1982).
10. G. A. Murrell and W. G. Rapeport. Clinical pharmacokinetics of allopurinol. Clin. Pharmacokinet. 11:343-353 (1986).
11. F. Y. Aoki and D. S. Sitar. Clinical pharmacokinetics of amantadine hydrochloride. Clin. Pharmacokinet. 14:35-51 (1988).
12. M. F. Grayson, A. J. Smith, and R. N. Smith. Absorption distribution and elimination of 14 C-amiloride in normal human subjects. Br. J. Pharmacol. 43:473P-474P (1971).
13. R. J. Santen and R. I. Misbin. Aminoglutethimide review of pharmacology and clinical use. Pharmacotherapy 1:95-120 (1981).
14. D. Fausa and K. Rasmussen. Amiodarone-a dangerous wonder drug. Review of the literature and personal experiences. Tidsskr. Nor. Laegeforen. 106:403-406 (1986).
15. I. Popiliev. Amiodarone pharmacology clinical use and side effects. Vutr. Boles. 24:17-25 (1985).
16. P. Schulz, K. Turner-Tamiyasu, and G. Smith. Amitriptyline disposition in young and elderly normal men. Clin. Pharmacol. Ther. 33:360-366 (1983).
17. K. Laine, K. T. Kivistö, I. Laakso, and P. Neuvonen. Prevention of amlodipine absorption by activated charcoal effect of delay in charcoal administration. Br. J. Clin. Pharmacol. 43:29-33 (1997).
18. K. H. Jones and S. A. Hill. The toxicology absorption and pharmacokinetics of amoxicillin. Adv. Clin. Pharmacol. 7:20 (1974).
19. E. J. Triggs, J. M. Johnson, and B. Learoyd. Absorption and disposition of ampicillin in the elderly. Eur. J. Clin. Pharmacol. 18:195-198 (1980).
20. N. Muir, J. D. Nichols, M. Stillings, and J. Sykes. The influence of dosage form on aspirin kinetics implications for acute cardiovascular use. Curr. Med. Res. Opin. 13:547-553 (1997).
21. F. Bochner and J. V. Lloyd. Aspirin for myocardial infarction clinical pharmacokinetic considerations. Clin. Pharmacokinet. 28:433-438 (1995).
22. M. L. Buck, D. Wiest, and P. C. Gillette. Pharmacokinetics and pharmacodynamics of atenolol in children. Clin. Pharmacol. Ther. 46:629-633 (1989).
23. D. M. Gibson, N. J. Bron, and A. Richens. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J. Clin. Pharmacol. 36:242-246 (1996).
24. E. H. Ellinwood Jr., A. M. Nikaido, S. K. Gupta, D. G. Heatherly, and J. K. Nishita. Comparison of central nervous system and peripheral pharmacodynamics to atropine pharmacokinetics. J. Pharmacol. Exp. Ther. 255:1133-1139 (1990).
25. K. Tsutsumi, Y. Otsuki, and T. Kinoshita. Simultaneous determination of azathioprine and 6-mercaptopurine in serum by reversed-phase high-performance liquid chromatography. J. Chromatogr. 231:392-399 (1982).
26. E. W. Wuis, M. J. Dirks, E. F. Termond, T. B. Vree, and E. van der Kleijn. Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur. J. Clin. Pharmacol. 37:181-184 (1989).
27. J. McAinsh, B. F. Holmes, and N. S. Baber, and J. Young. Bioavailability of propranolol and bendrofluazide formulations. Biopharm. Drug Dispos. 2: 167-175 (1981).
28. M. C. Petersen, R. L. Nation, W. G. McBride, J. J. Ashley, and R. G. Moore. Pharmacokinetics of betamethasone in healthy adults after intravenous administration. Eur. J. Clin. Pharmacol. 25:643-650 (1983).
29. A. N. de Groot, P. W. van Dongen, and T. B. Vree. Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs 56:523-535 (1998).
30. A. Ward and R. C. Heel. Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 28:426-464 (1984).
31. R. Mäntylä, P. T. Männistö, A. Vuorela, S. Sundberg, and P. Ottoila. Impairment of captopril bioavailability by concomitant food and antacid intake. Int. J. Clin. Pharmacol. Ther. Toxicol. 22:626-629 (1984).
32. H. Liu and M. Delgado. Influence of sex, age, weight, and carbamazepine dose on serum concentrations concentration ratios and level/dose ratios of carbamazepine and its metabolites. Ther. Drug Monit. 16:469-476 (1994).
33. T. Bergan and T. Midtvedt, and J. Erikssen. Human pharmacokinetics of cephalexin. Pharmacology 4:264-272 (1970).
34. A. Mulhall and J. de Louvois. The monitoring of serum chloramphenicol levels in children with severe infections. J. Antimicrob. Chemother. 16:809-810 (1985).
35. E. I. Minder. Toxicity in a case of acute and massive overdose of chlordiazepoxide and its correlation to blood concentration. J. Toxicol. Clin. Toxicol. 27:117-127 (1989).
36. G. I. Adebayo and A. F. Mabadeje. Chlorothiazide absorption in humans-possible example of Michaelis-Menten kinetics. Pharmacology 31:181-188 (1985).
37. P. R. Farina, T. R. MacGregor, S. T. Horhota, and J. J. Keirns. Relative bioavailability of chlorthalidone in humans after single oral doses. J. Pharm. Sci. 74:995-998 (1985).
38. J. Lesko, R. Chandrasekharan, and G. L. Amidon. Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans correlation with antral gastric motility. Eur. J. Pharm. Biopharm. 53:37-47 (2002).
39. A. Somogyi and R. Gugler. Clinical pharmacokinetics of cimetidine. Clin. Pharmacokinet. 8:463-495 (1983).
40. N. Takamatsu, L. S. Welage, Y. Hayashi, R. Yamamoto, J. L. Barnett, V. P. Shah, L. A. Bayer, A. Gajewska, and M. Stephens. Pharmacokinetics of ciprofloxacin in the elderly. Respiration 51:292-295 (1987).
41. D. M. Campoli-Richards, J. P. Monk, and A. Price. Ciprofloxacin. A review of its antibacterial activity pharmacokinetic properties and therapeutic use. Drugs 35:373-447 (1988).
42. J. Liliemark. The clinical pharmacokinetics of cladribine. Clin. Pharmacokinet. 32:120-131 (1997).
43. J. D. Panzer, D. C. Brown, W. L. Epstein, R. L. Lipson, H. W. Mahaffey, and W. H. Atkinson. Clindamycin levels in various body tissues and fluids. J. Clin. Pharmacol. New Drugs 12:259-262 (1972).
44. Y. Sawae and M. Takii. Preclinical and clinical studies of clindamycin-2-phosphate. Jpn. J. Antibiot. 30:42-50 (1977).
45. G. J. Yakatan, W. J. Poynor, R. L. Talbert, B. F. Floyd, C. L. Slough, R. S. Ampulski, and J. J. Benedict. Clodronate kinetics and bioavailability. Clin. Pharmacol. Ther. 31:402-410 (1982).
46. H. Naito, M. Wachi, and M. Nishida. Clinical effects and plasma concentrations of long-term clonazepam monotherapy in previously untreated epileptics. Acta Neurol. Scand. 76:58-63 (1987).
47. P. Manhem, L. Paalzow, and B. Hökfelt. Plasma clonidine in relation to blood pressure catecholamines and renin activity during long-term treatment of hypertension. Clin. Pharmacol. Ther. 31:445-451 (1982).
48. G. Nergelius, E. Vinge, H. I. Bengtsson, R. Björkman, and A. Grubb. No effect of diclofenac on the pharmacokinetics of cloxacillin. Pharmacol. Toxicol. 81:26-30 (1997).
49. S. R. Walker, M. E. Evans, A. J. Richards, and J. W. Paterson. The fate of (14 C)disodium cromoglycate in man. J. Pharm. Pharmacol. 24:525-531 (1972).
50. M. Colvin and J. Hilton. Pharmacology of cyclophosphamide and metabolites. Cancer Treat. Rep. 65:89-95 (1981).
51. A. Ahmed and S. Hombal. Cyclophosphamide (Cytoxan(r)). A review on relevant pharmacology and clinical uses. J. Am. Acad. Dermatol. 11:1115-1126 (1984).
52. M. J. Moore. Clinical pharamcokinetics of cyclophosphamide. Clin. Pharmacokinet. 20:194-208 (1991).
53. R. L. Capizzi, J. C. White, and B. L. Powell. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin. Hematol. 28:54-69 (1991).
54. T. R. Brophy, J. McCafferty, and J. H. Tyrer. Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. Eur. J. Clin. Pharmacol. 24:103-108 (1983).
55. M. M. Reidenberg, M. Levy, and H. Warner. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin. Pharmacol. Ther. 23:371-374 (1978).
56. G. R. Donowitz and G. L. Mandell. Beta-lactam antibiotics. N. Engl. J. Med. 318:419-426 (1988).
57. D. Faulds and R. N. Brogden. Didanosine: a review of its antiviral activity pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 44:94-116 (1992).
58. C. M. Perry and J. A. Balfour. Didanosine. An update on its antiviral activity, pharmacokinetic properties, and therapeutic efficacy in the management of HIV disease. Drugs 52:928-962 (1996).
59. C. S. Cook, S. J. McDonald, and A. Karim. Importance of pharmacokinetic and physicochemical data in the discovery and development of novel anti-arrhythmic drugs. Xenobiotica 23:1299-1309 (1993).
60. E. Dempsey, S. Bourque, J. Spenard, and H. Landriault. Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers. J. Clin. Pharmacol. 36: 903-910 (1996).
61. J. Heykants, R. Hendriks, W. Meuldermans, M. Michiels, H. Scheygrond, and H. Reyntjens. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur. J. Drug Metab. Pharmacokinet. 6:61-70 (1981).
62. K. J. Barrington, N. N. Finer, G. Torok-Both, F. Jamali, and R. T. Coutts. Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity. Pediatrics 80:22-27 (1987).
63. D. R. Abernethy and E. L. Todd. Doxepin-cimetidine interaction: Increased doxepin bioavailability during cimetidine treatment. J. Clin. Psychopharmacol. 6:8-12 (1986).
64. A. Pourtier-Manzanedo, A. Didier, S. Froidevaux, and F. Loor. Lymphotoxicity and myelotoxicity of doxorubicin and SDZ PSC 833 combined chemotherapies for normal mice. Toxicology 99: 207-217 (1995).
65. S. Saivin and G. Houin. Clinical pharmacokinetics of doxycycline and minocycline. Clin. Pharmacokinet. 15:355-366 (1988).
66. P. A. Todd and K. L. Goa. Enalapril: a reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 43:346-381 (1992).
67. P. A. Todd and P. C. Heel. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypotension and congestive heart failure. Drugs 31:198-248 (1986).
68. H. J. Gomez, V. J. Cirillo, and J. D. Irvin. Enalapril: a review of human pharmacology. Drugs 30:13-24 (1985).
69. I. Strauss and F. Erhardt. Ethambutol absorption, excretion and dosage in patients with renal tuberculosis. Chemotherapy 15: 148-157 (1970).
70. J. W. Goldzieher and S. A. Brody. Pharmacokinetics of ethinyl estradiol and mestranol. Am. J. Obstet. Gynecol. 163:2114-2119 (1990).
71. G. Toffoli, G. Corona, R. Sorio, I. Robieux, B. Basso, A. M. Colussi, and M. Boiocchi. Population pharmacokinetics and pharmacodynamics of oral etoposide. Br. J. Clin. Pharmacol. 52:511-519 (2001).
72. R. P. Gural, V. S. Chungi, R. P. Shrewsbury, and L. W. Dittert. Dose-dependent absorption of disodium etidronate. J. Pharm. Pharmacol. 37:443-445 (1985).
73. L. P. James and G. L. Kearns. Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. Clin. Pharmacokinet. 31:103-110 (1996).
74. P. A. Todd and D. Faulds. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs 44:251-277 (1992).
75. F. E. Simons, J. N. Bergman, W. T. Watson, and K. J. Simons. The clinical pharmacology of fexofenadine in children. J. Allergy Clin. Immunol. 98:1062-1064 (1996).
76. J. C. Perry and A. Garson Jr. Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. Am. Heart J. 124:1614-1621 (1992).
77. B. R. Winkelmann and H. Leinberger. Life-threatening flecainide toxicity. A pharmacodynamic approach. Ann. Intern. Med. 106:807-814 (1987).
78. S. M. Grant and S. P. Clissold. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs 39: 877-916 (1990).
79. C. A. Lyman and T. J. Walsh. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44:9-35 (1992).
80. H. G. Boxenbaum, H. N. Posmanter, T. Macasieb, K. A. Geitner, R. E. Weinfeld, J. D. Moore, A. Darragh, D. A. O'Kelly, L. Weissman, and S. A. Kaplan. Pharmacokinetics of flunitrazepam following single-and multiple-dose oral administration to healthy human subjects. J. Pharmacokin. Biopharm. 6:283-293 (1978).
81. R. B. Diasio and B. E. Harris. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16:215-237 (1989).
82. L. A. Jokubaitis. Development and pharmacology of fluvastatin. Br. J. Clin. Pract. 77A:11-15 (1996).
83. R. E. Cutler, A. W. Forrey, T. G. Christopher, and B. M. Kimpel. Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. Clin. Pharmacol. Ther. 15:588-596 (1974).
84. L. L. Ponto and R. D. Schoenwald. Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review, Part I. Clin. Pharmacokinet. 18:381-408 (1990).
85. L. L. Ponto and R. D. Schoenwald. Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review, Part II. Clin. Pharmacokinet. 18: 460-471 (1990).
86. K. L. Goa and E. M. Sorkin. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs 46:409-427 (1993).
87. P. A. Todd and A. Ward. Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 36:314-339 (1988).
88. J. G. Pearson. Pharmacokinetics of glyburide. Am. J. Med. 79: 67-71 (1985).
89. T. L. Schwinghammer, E. J. Antal, R. T. Kubacka, M. E. Hackimer, and J. M. Johnston. Pharmacokinetics and pharmacodynamics of glyburide in young and elderly nondiabetic adults. Clin. Pharm. 19:532-538 (1991).
90. W. A. Kradjan, K. A. Kobayashi, L. A. Bauer, J. R. Horn, K. E. Opheim, and F. J. Wood Jr. Glipizide pharmacokinetics: effects of age, diabetes, and multiple dosing. J. Clin. Pharmacol. 29: 1121-1127 (1989).
91. W. A. Kradjan, K. Y. Takeuchi, K. E. Opheim, and F. C. Wood Jr. Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. Pharmacotherapy 15:465-471 (1995).
92. E. Wahlin-Boll, L. O. Almer, and A. Melander. Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. Clin. Pharmacokinet. 7:363-372 (1982).
93. P. L. Morselli, G. Bianchetti, and M. Dugas. Haloperidol plasma level monitoring in neuropsychiatric patients. Ther. Drug Monit. 4:51-58 (1982).
94. T. T. Sproat and L. M. Lopez. Hypertension. In J. C. Delafuente and R. B. Stewart (eds.), Therapeutics in the Elderly, Harvey Whitney Books, Cincinnati, 1995, pp. 228-246.
95. J. H. Allen, J. M. McKenney, M. A. Stratton, and K. Link. Antihypertensive effect of hydrochlorothiazide administered once or twice daily. Clin. Pharm. 1:239-243 (1982).
96. N. M. Davies. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin. Pharmacokinet. 34:101-154 (1998).
97. P. Borchmann, K. Hubel, R. Schnell, and A. Engert. Idarubicin: a brief overview on pharmacology and clinical use. Int. J. Clin. Pharmacol. Ther. 35:80-83 (1997).
98. L. M. Hollingshead and D. Faulds. Idarubicin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 42:690-719 (1991).
99. A. Nagy and R. Johansson. Plasma levels of imipramine and desipramine in man after different routes of administration. Naunyn-Schmiedebergs Arch. Pharmacol. 290:145-160 (1975).
100. Mims Australia. Mims Annual. Intercontinental Medical Statistics, Crows Nest NSW, 1999.
101. P. M. Brooks, M. A. Bell, J. J. Walker, A. C. Kennedy, R. D. Sturrock, and W. C. Dick. Proceedings: ups and downs of indomethacin bioavailability. Ann. Rheum. Dis. 34: (1975).
102. P. E. Groth and J. M. Dunn. Bioavailability of indomethacin tablets in men volunteers. Clin. Pharm. 5:820-824 (1986).
103. M. A. Munger and S. M. Furniss. Angiotensin II receptor blockers: novel therapy for heart failure? Pharmacotherapy 16:59S-68S (1996).
104. J. O. Parker, B. Farrell, K. A. Lahey, and G. Moe. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N. Engl. J. Med. 316:1440-1444 (1987).
105. E. Nakashima, J. F. Rigod, E. T. Lin, and L. Z. Benet. Pharmacokinetics of nitroglycerin and its dinitrate metabolites over a thirtyfold range of oral doses. Clin. Pharmacol. Ther. 47:592-598 (1990).
106. U. W. Abshagen. Pharmacokinetics of isosorbide mononitrate. Am. J. Cardiol. 70:61G-66G (1992).
107. J. Clements and W. S. Nimmo. Pharmacokinetics and analgesic effect of ketamine in man. Br. J. Anaesth. 53:27-30 (1981).
108. S. A. Cooper. Ketoprofen in oral surgery pain: a review. J. Clin. Pharmacol. 21:S40-S46 (1988).
109. E. P. MacCarthy and S. S. Bloomfield. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects. Pharmacotherapy 3:193-219 (1983).
110. J. J. McNeil and W. J. Louis. Clinical pharmacokinetics of labetalol. Clin. Pharmacokinet. 9:157-167 (1984).
111. M. A. Johnson, G. A. Verpooten, M. J. Daniel, R. Plumb, J. Moss, D. Vancaesbroeck, and M. E. Debroe. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br. J. Clin. Pharmacol. 46:21-27 (1998).
112. C. M. Perry and D. Faulds. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 53:657-680 (1997).
113. A. F. Cohen, G. S. Land, D. D. Breimer, W. C. Yuen, C. Winton, and A. W. Peck. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther. 42:535-541 (1987).
114. A. Fitton and K. L. Goa. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 50:691-713 (1995).
115. A. H. Chun, C. J. Eason, H. H. Shi, and J. H. Cavanaugh. Lansoprazole: an alternative method of administration of a capsule dosage formulation. Clin. Ther. 17:441-447 (1995).
116. T. T. Doan, Q. Wang, J. S. Griffin, N. L. Lukasik, R. F. O'Dea, and W. J. Pan. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. Am. J. Health Syst. Pharm. 58:1512-1519 (2001).
117. J. G. Nutt and J. H. Fellman. Pharmacokinetics of levodopa. Clin. Neuropharmacol. 7:35-49 (1984).
118. L. M. Wing, J. O. Miners, D. J. Birkett, T. Foenander, K. Lillywhite, and S. Wanwimolruk. Lidocaine disposition - sex differences and effects of cimetidine. Clin. Pharmacol. Ther. 35: 695-701 (1984).
119. H. J. Gomez, V. J. Cirillo, and F. Moncloa. The clinical pharmacology of lisinopril. J. Cardiovasc. Pharmacol. 9:S27-S34 (1987).
120. D. R. Belanger, M. G. Tierney, and G. Dickinson. Effect of sodium polystyrene sulfonate on lithium bioavailability. Ann. Emerg. Med. 21:1312-1325 (1992).
121. D. J. Greenblatt, M. D. Allen, A. Locniskar, J. S. Harmatz, and R. I. Shader. Lorazepam kinetics in the elderly. Clin. Pharmacol. Ther. 26:103-113 (1979).
122. H. R. Brunner, Y. Christen, A. Munafo, R. J. Lee, B. Waeber, and J. Nussberger. Clinical experience with angiotensin II receptor antagonists. Am. J. Hypertens. 5:243S-246S (1992).
123. R. R. Miller and H. Jick. Clinical effects of meperidine in hospitalized medical patients. J. Clin. Pharmacol. 18:180-189 (1978).
124. B. Bostrom and G. Erdmann. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am. J. Pediatr. Hematol. Oncol. 15:80-86 (1993).
125. G. B. Elion. Biochemistry and pharmacology of purine analogs. Fed. Proc. 26:898-904 (1967).
126. T. L. Loo, J. K. Luce, M. P. Sullivan, and E. Frei Iii. Clinical pharmacologic observations on 6-mercaptopurine and 6-methylthiopurine ribonucleoside. Clin. Pharmacol. Ther. 9:180-194 (1968).
127. C. J. Dunn and D. H. Peters. Metformin: a review of its pharmacologic properties and therapeutic use in diabetes mellitus. Drugs 49:721-749 (1995).
128. W. A. Bleyer. Clinical pharmacology of intrathecal methotrexate II. An approved dosage regimen derived from age-related pharmacokinetics. Cancer Treat. Rep. 61:1419-1425 (1977).
129. N. R. Campbell, A. Skerjanec, Y. Tam, S. Robertson, and E. Burgess. Methyldopa kinetics before and after ingestion of methyldopa for eight weeks. Eur. J. Clin. Pharmacol. 48:397-400 (1995).
130. K. M. Tornatore, G. Logue, R. C. Venuto, and P. J. Davis. Pharmacokinetics of methylprednisolone in elderly and young healthy males. J. Am. Geriatr. Soc. 42:1118-1122 (1994).
131. K. Lauritsen, L. S. Laursen, and J. Rask-Madsen. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part I). Clin. Pharmacokinet. 19:11-31 (1990).
132. E. T. Shore, D. Cepin, and M. J. Davidson. Metoprolol overdose. Ann. Emerg. Med. 10:524-527 (1981).
133. C. D. Freeman, N. E. Klutman, and K. C. Lamp. Metronidazole. A therapeutic review and update. Drugs 54:679-708 (1997).
134. J. P. Monk and R. N. Brogden. Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs 40:374-411 (1990).
135. C. J. Timmer, S. Pourbaix, J. P. Desager, M. Sclavons, and C. Harvengt. Absolute bioavailability of mianserin tablets and solution in healthy humans. Eur. J. Drug Metab. Pharmacokinet. 10:315-323 (1985).
136. F. P. Meyer. Minocycline for acne. Food reduces minocycline's bioavailability. BMJ 312:1101 (1996).
137. R. P. Walt. Misoprostol for the treatment of peptic ulcer and anti-inflammatory drug-induced gastroduodenal ulceration. N. Engl. J. Med. 327:1575-1580 (1992).
138. S. F. Brunk and M. Delle. Morphine metabolism in man. Clin. Pharmacol. Ther. 16:51-57 (1974).
139. H. L. June, M. L. Stitzer, and E. Cone. Acute physical dependence: time course and relation to human plasma morphine concentrations. Clin. Pharmacol. Ther. 57:270-280 (1995).
140. K. T. Olkkola, K. Hamunen, and E. L. Maunuksela. Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children. Clin. Pharmacokinet. 28:385-404 (1995).
141. E. Beyssac, F. Touaref, M. Meyer, L. Jacob, P. Sandouk, and J.-M. Aiache. Bioavailability of morphine after administration of a new bioadhesive buccal tablet. Biopharm. Drug Dispos. 19:401-405 (1998).
142. Anonymous. American academy of pediatrics committee on drugs: naloxone dosage and route of administration for infants and children: addendum to emergency drug doses for infants and children. Pediatrics 86:484-485 (1990).
143. M. A. Hussain, C. A. Koval, M. J. Myers, E. G. Shami, and E. Shefter. Improvement of the oral bioavailability of naltrexone in dogs: a prodrug approach. J. Pharm. Sci. 76:356-358 (1987).
144. R. E. Ferner, S. Monkman, J. Riley, S. Cholerton, J. R. Idle, and D. N. Bateman. Pharmacokinetics and toxic effects of nifedipine in massive overdose. Hum. Exp. Toxicol. 9:309-311 (1990).
145. E. A. Ramoska, H. A. Spiller, and A. Myers. Calcium channel blocker toxicity. Ann. Emerg. Med. 19:649-653 (1990).
146. H. R. Ochs, D. J. Greenblatt, R. Gugler, G. Müntefering, A. Locniskar, and D. R. Abernethy. Cimetidine impairs nitrazepam clearance. Clin. Pharmacol. Ther. 34:227-230 (1983).
147. J. T. Callaghan, R. F. Bergstrom, A. Rubin, S. Chernish, R. Crabtree, M. P. Knadler, B. Obermeyer, W. W. Offen, D. W. Schneck, and G. Aronoff. A pharmacokinetic profile of nizatidine in man. Scand. J. Gastroenterol. Suppl. 136:9-17 (1987).
148. R. Vargas, J. Ryan, F. G. McMahon, G. Regel, W. W. Offen, and C. Matsumoto. Pharmacokinetics and pharmacodynamics of oral nizatidine. J. Clin. Pharmacol. 28:71-75 (1988).
149. I. Nilsson-Ehle and B. Ljungberg. Quinolone disposition in the elderly: practical implications. Drugs Aging 1:279-288 (1991).
150. E. E. Kvist, A. Al-Shurbaji, M. L. Dahl, C. Nordin, G. Alvan, and L. Stahle. Quantitative pharmacogenetics of nortriptyline: a novel approach. Clin. Pharmacokinet. 40:869-877 (2001).
151. B. Lipper and B. D. Gaynor. Value of serum tricyclic antidepressant levels with massive nortriptyline overdose and persistent hypotension. Am. J. Emerg. Med. 13:107 (1995).
152. S. Dawling, P. Crome, and R. Braithwaite. Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young healthy volunteers. Clin. Pharmacokinet. 5: 394-401 (1980).
153. T. Andersson. Omeprazole drug interaction studies. Clin. Pharmacokinet. 21:195-212 (1991).
154. F. Massoomi, J. Savage, and C. J. Destache. Omeprazole: a comprehensive review. Pharmacotherapy 13:46-59 (1993).
155. F. Roila and A. Del Favero. Ondansetron clinical pharmacokinetics. Clin. Pharmacokinet. 29:95-109 (1995).
156. K. H. Simpson and F. M. Hicks. Clinical pharmaco-kinetics of ondansetron: a review. J. Pharm. Pharmacol. 48:774-781 (1996).
157. M. W. Jann, T. L. ZumBrunnen, S. N. Tenjarla, E. S. Ward Jr., and D. J. Weidler. Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy 18:288-294 (1998).
158. B. J. Chaffee and R. M. Tankanow. Ondansetron-the first of a new class of antiemetic agents. Clin. Pharm. 10:430-436 (1991).
159. S. E. Leucuta, M. Follidis, R. Capalneanu, and A. Mocan. Relative bioavailability of different oral sustained release oxprenolol tablets. Eur. J. Drug Metab. Pharmacokinet. 23:178-184 (1998).
160. E. Kalso and A. Vainio. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin. Pharmacol. Ther. 47:639-646 (1990).
161. A. Fitton and D. McTavish. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41: 289-318 (1991).
162. R. Huber, M. Hartmann, H. Bliesath, R. Luhmann, V. W. Steinijans, and K. Zech. Pharmacokinetics of pantoprazole in man. Int. J. Clin. Pharmacol. Ther. 34:S7-16 (1996).
163. N. Muir, J. D. Nichols, J. M. Clifford, M. R. Stillings, and R. Hoare. Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Curr. Med. Res. Opin. 13:491-500 (1997).
164. W. J. Shih, J. Fong, and M. L. Gora. Meperidine in conjunction with cholescintigraphy to diagnose acute cholecystitis in a patient allergic to morphine. Clin. Nucl. Med. 19:981-984 (1994).
165. R. Gugler, C. V. Manion, and D. L. Azarnoff. Phenytoin: pharmacokinetics and bioavailability. Clin. Pharmacol. Ther. 19:135-142 (1992).
166. N. P. Chau, Y. A. Weiss, M. E. Safar, D. E. Lavene, D. R. Georges, and P. L. Milliez. Pindolol availability in hypertensive patients with normal and impaired renal function. Clin. Pharmacol. Ther. 22:505-510 (1977).
167. D. McTavish and E. M. Sorkin. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 42:65-89 (1991).
168. H. Mikami and T. Ogihara. Therapeutic drug monitoring of alpha-blocker, prazosin. Jpn. J. Clin. Med. 48:1143-1144 (1990).
169. P. A. Reece. Quantification of prazosin in plasma by high-performance liquid chromatography. J. Chromatogr. 221:188-192 (1980).
170. G. Rostock, H. D. Faulhaber, P. Unger, V. Homuth, C. Prehm, and R. Günzel. Comparative study of the relative bioavailabilities of two prazosin preparations in patients with essential hypertension. Pharmazie 40:259-261 (1985).
171. S. Watanabe, C. Kuyama, S. Yokoyama, S. Kubo, and H. Iwai. Distribution of plasma phenobarbital, diphenylhydantoin and primidone levels in epileptic patients. Folia Psychiatr. Neurol. Jap. 31:205-217 (1977).
172. H. E. Booker, K. Hosokowa, R. D. Burdette, and B. Darcey. A clinical study of serum primidone levels. Epilepsia 11:395-402 (1970).
173. J. Koch-Weser. Serum procainamide levels as therapeutic guides. Clin. Pharmacokinet. 2:389-402 (1977).
174. R. A. Tokola. The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. Cephalalgia 8:139-147 (1988).
175. T. L. Schwinghammer, R. P. Juhl, L. W. Dittert, S. K. Melethil, F. J. Kroboth, and V. S. Chung. Comparison of the bioavailability of oral, rectal and intramuscular promethazine. Biopharm. Drug Dispos. 5:185-194 (1984).
176. S. G. Barnwell, S. J. Burns, S. Higginbottom, I. Whelan, D. Corness, G. Hay, E. Rosenberg, and D. Attwood. Demonstration of the importance of biphasic oleic acid delivery for enhancing the bioavailability of propranolol in healthy volunteers. Int. J. Pharm. 128:145-154 (1996).
177. C. G. Duarte, A. C. Polizello, A. I. Assis-Pandochi, and A. C. Spadaro. Optimization of HPLC analysis for the determination of propylthiouracil levels in plasma and serum. J. Pharm. Biomed. Anal. 23:237-241 (2000).
178. A. M. Horvath, D. Pilon, G. Caillé, W. A. Colburn, J. J. Ferry, G. J. Frank, Y. Lacasse, and S. C. Olson. Multiple-dose propranolol administration does not influence the single dose pharmacokinetics of quin and its active metabolite (quinat). Biopharm. Drug Dispos. 11:191-196 (1990).
179. C. N. Verme, T. M. Ludden, W. A. Clementi, and S. C. Harris. Pharmacokinetics of quinidine in male patients. A population analysis. Clin. Pharmacokinet. 22:468-480 (1992).
180. J. Kindler, H. Schunkert, M. Gassmann, W. Lahn, R. Irmisch, E. R. Debusmann, J. Ocón-Pujadas, E. Ritz, and H. G. Sieberth. Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure. J. Cardiovasc. Pharmacol. 13:S55-S58 (1989).
181. S. M. Grant, H. D. Langtry, and R. N. Brogden. Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 37:801-870 (1989).
182. D. F. Smee, R. W. Sidwell, B. B. Barnett, and R. S. Spendlove. Bioassay system for determining ribavirin levels in human serum and urine. Chemotherapy 27:1-11 (1981).
183. G. Gatti, N. Barzaghi, G. Attardo Parrinello, B. Vitiello, and E. Perucca. Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects. Int. J. Clin. Pharmacol. Res. 9:385-389 (1989).
184. F. Trebini, D. Daniele, S. Gillio, and L. Scarzella. Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome. Acta Neurol. Scand. 7:432-439 (1985).
185. M. N. Gordon, C. D. Muller, K. A. Sherman, D. G. Morgan, A. J. Azzaro, and L. Wecker. Oral versus transdermal selegiline: antidepressant-like activity in rats. Pharmacol. Biochem. Behav. 63:501-506 (1999).
186. E. Grau, M. Perella, and E. Pastor. Simvastatin-oral anticoagulant interaction. Lancet 347:405-6 (1996).
187. A. Fitton and E. M. Sorkin. Sotalol: an updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias. Drugs 46:678-719 (1993).
188. P. Kahela, M. Anttila, R. Tikkanen, and H. Sundquist. Effect of food, food constituents and fluid on the bioavailability of sotalol. Acta Pharmacol. Toxicol. 44:7-12 (1979).
189. W. R. Bartle, P. E. Coates, M. M. Fisher, and F. J. Louman. Effect of neomycin on the bioavailability of spironolactone: a single-dose study. Am. J. Hosp. Pharm. 36:1701-1703 (1979).
190. E. B. Lewin, J. O. Klein, and M. Finland. Trimethoprimsulfamethoxazole: absorption, excretion, and toxicity in six children. J. Infect. Dis. 128:S618-S621 (1973).
191. E. R. Garrett, R. S. Süverkrup, K. Eberst, R. L. Yost, and J. P. O'Leary. Surgically affected sulfisoxazole pharmacokinetics in the morbidly obese. Biopharm. Drug Dispos. 2:329-365 (1981).
192. V. F. Cosson and E. Fuseau. Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients. J. Pharmacokin. Biopharm. 27:149-171 (1999).
193. P. E. Warner, K. L. Brouwer, E. K. Hussey, G. E. Dukes, W. D. Heizer, K. H. Donn, I. M. Davis, and J. R. Powell. Sumatriptan absorption from different regions of the human gastrointestinal tract. Pharm. Res. 12:138-143 (1995).
194. W. J. Krall, J. J. Sramek, and N. R. Cutler. Cholinesterase inhibitors:
195. P. D. Kroboth, R. B. Smith, R. Rault, M. R. Silver, M. I. Sorkin, J. B. Puschett, and R. P. Juhl. Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. Clin. Pharmacol. Ther. 37:453-459 (1985).
196. H. E. Hosie and W. S. Nimmo. Temazepam absorption in patients before surgery. Br. J. Anaesth. 66:20-24 (1991).
197. L. Borgström, C. X. Liu, and A. Walhagen. Pharmacokinetics of the enantiomers of terbutaline after repeated oral dosing with racemic terbutaline. Chirality 1:174-177 (1989).
198. U. Täuber, K. Schröder, B. Düsterberg, and H. Matthes. Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. Eur. J. Drug Metab. Pharmacokinet. 11:145-149 (1986).
199. K. S. Albert, R. D. Welch, K. A. De Sante, and A. R. Di Santo. Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture. J. Pharm. Sci. 68:586-588 (1979).
200. P. A. Kramer, D. J. Chapron, J. Bens̈on, and S. A. Mercik. Tetracycline absorption in elderly patients with achlorhydria. Clin. Pharmacol. Ther. 23:467-472 (1978).
201. N. Rojanasthien, K. Kovjiriyapan, M. Manorot, and C. Pothirat. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. Asian Pac. J. Allergy Immunol. 19:69-78 (2001).
202. S. Massa, G. Stefancich, M. Artico, F. Corelli, G. C. Pantaleoni, G. Palumbo, D. Fanini, and R. Giorgi. Non-steroidal anti-inflammatory agents. IV. Synthesis and pharmacologic activity of aroylthiopheneacetic acids with a pyrrole group. Farmaco 41:281-291 (1986).
203. R. Sutinen, P. Paronen, V. Saano, and A. Urtti. Water-activated, pH-controlled patch in transdermal administration of timolol. II. Drug absorption and skin irritation. Eur. J. Pharm. Sci. 11: 25-31 (2000).
204. E. J. Antal, W. R. Gillespie, J. P. Phillips, and K. S. Albert. The effect of food on the bioavailability and pharmacodynamics of tolbutamide in diabetic patients. Eur. J. Clin. Pharmacol. 22: 459-462 (1982).
205. W. Mühlberg, E. Mutschler, A. Hofner, H. Spahn-Langguth, and O. Arnold. The influence of age on the pharmacokinetics and pharmacodynamics of bemetizide and triamterene: a single and multiple dose study. Arch. Gerontol. Geriatr. 32:265-273 (2001).
206. V. Heimsoth, D. Loew, and O. Schuster. Pharmacodynamics and pharmacokinetics of furosemide-retard and furosemide-retard/triamterene. Eur. J. Drug Metab. Pharmacokinet. 13:161-164 (1988).
207. R. L. Williams, J. Mordenti, R. A. Upton, E. T. Lin, W. L. Gee, C. D. Blume, and L. Z. Benet. Effects of formulation and food on the absorption of hydrochlorothiazide and triamterene or amiloride from combination diuretic products. Pharm. Res. 4: 348-352 (1987).
208. H. Klinker, P. Langmann, M. Zilly, and E. Richter. Drug monitoring during the treatment of AIDS-associated pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole. J. Clin. Pharm. Therap. 23:149-154 (1998).
209. T. Meshi and Y. Sato. Studies on sulfamethoxazole-trimethoprim. Absorption, distribution, excretion and metabolism of trimethoprim in rat. Chem. Pharm. Bull. 20:2079-2090 (1972).
210. G. Caillé, J. G. Besner, Y. Lacasse, and M. Vézina. Pharmacokinetic characteristics of two different formulations of trimipramine determined with a new GLC method. Biopharm. Drug Dispos. 1:187-194 (1980).
211. F. Kees, L. Farber, M. Bucher, G. Mair, K. Morike, and H. Grobecker. Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Br. J. Clin. Pharmacol. 52:705-707 (2001).
212. R. Davis, D. H. Peters, and D. McTavish. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47:332-372 (1994).
213. D. McTavish. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 38:19-76 (1989).
214. F. O. Müller, J. M. Steyn, H. K. Hundt, and H. G. Luus. Warfarin bio-availability. A comparison of 4 products. S. Afr. Med. J. 74:566-567 (1988).
215. J. M. Adams, M. J. Shelton, R. G. Hewitt, M. DeRemer, R. Di Francesco, T. H. Grasela, and G. D. Morse. Zalcitabine population pharmacokinetics: application of radioimmunoassay. Antimicrob. Agents Chemother. 42:409-413 (1998).
216. A. Guarino, F. Albano, A. Castaldo, M. I. Spagnuolo, and R. B. Canani. Intestinal malabsorption and zidovudine bioavailability. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18:91-92 (1998).
217. I. Gutman, O. Miljkovi, G. Caporossi, and P. Hansen. Alkanes with small and large Randic connectivity indices. Chem. Phys. Lett. 306:366-372 (1999).
218. L. B. Kier and L. H. Hall. Molecular Connectivity in Chemistry and Drug Research, Academic Press, New York, 1976.
219. M. Randic. Novel shape descriptors for molecular graphs. J. Chem. Inf. Comput. Sci. 41:607-613 (2001).
220. J. Galvez, R. Garciadomenech, V. Dejulianortiz, and R. Soler. Topological approach to analgesia. J. Chem. Inf. Comput. Sci. 34:1198-1203 (1994).
221. N. Trinajstic. Chemical Graph Theory, CRC Press, Boca Raton, 1992.
222. F. Burden. A chemically intuitive molecular index based on the eigenvalues of a modified adjacency matrix. Quant. Struct.-Act. Relat. 16:309-314 (1997).
223. R. O. Potts and R. H. Guy. The influence of molecular volume and hydrogen-bonding on peptide transport across epithelial membranes. Pharm. Res. 10:635-637 (1993).
224. M. Genty, G. González, C. Clere, V. Desangle-Gouty, and J. Y. D. Legendre. Determination of the passive absorption through the rat intestine using chromatographic indices and molar volume. Eur. J. Pharm. Sci. 12:223-229 (2001).
225. C. Hansch. Substituent Constants for Correlation Analysis in Chemistry and Biology, Umi Research Press, New York, 1979.
226. V. N. Viswanadhan, A. K. Ghose, G. R. Revankar, and R. K. Robins. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J. Chem. Inf. Comput. Sci. 29:163-172 (1989).
227. N. Bodor and P. Buchwald. Octanol-water partition searching for predictive models. Curr. Med. Chem. 5:353-380 (1998).
228. Z. Meng and W. R. Carper. Effects of hydration on the molecular structure of metal ion-atrazine dimer complexes a MOPAC (PM3) study. J. Mol. Struct. Theochem. 531:89-98 (2000).
229. P. Ertl, B. Rohde, and P. Selzer. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 43:3714-3717 (2000).
230. G. Klopman and H. Zhu. Estimation of the aqueous solubility of organic molecules by the group contribution approach. J. Chem. Inf. Comput. Sci. 41:439-445 (2001).
231. G. C. Cash and R. G. Clements. Comparison of structure-activity relationships derived from two methods for estimating octanol-water partition coefficients. SAR QSAR Environ. Res. 5:113-124 (1996).
232. G. Klopman, C. M. Ding, and O. T. Macina. Computer aided olive oil-gas partition coefficient calculations. J. Chem. Inf. Comput. Sci. 37:569-575 (1997).
233. R. Reed. Pruning algorithms - a survey. IEEE Trans. Neural Netw. 4:740-747 (1993).
234. E. Derks, M. S. S. Pastor, and L. M. C. Buydens. Robustness analysis of radial base function and multi-layered feed-forward neural network models. Chem. Intell. Lab. Syst. 28:49-60 (1995).
235. S. Winiwarter, N. M. Bonham, F. Ax, A. Hallberg, H. Lennernas, and A. Karlen. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41:4939-4949 (1998).
236. K. Palm. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14:568-571 (1997).
237. R. B. Hermann. Modeling hydrophobic solvation of nonspherical systems comparison of use of molecular surface area with accessible surface area. J. Comput. Chem. 18:115-125 (1997).
238. N. Bodor and M. J. Huang. A new method for the estimating of the aqueous solubility of organic compounds. J. Pharm. Sci. 81:954-960 (1992).
239. T. Ooi, M. Oobatake, G. Némethy, and H. A. Scheraga. Accessible surface areas as a measure of the thermodynamic parameters of hydration of peptides. Proc. Natl. Acad. Sci. USA 84: 3086-3090 (1987).
240. W. J. Dunn III, M. G. Koehler, and S. Grigoras. The role of solvent-accessible surface area in determining partition coefficients. J. Med. Chem. 30:1121-1126 (1987).
241. S. O. Shan and D. Herschlag. The change in hydrogen bond strength accompanying charge rearrangement - implications for enzymatic catalysis. Proc. Natl. Acad. Sci. USA 93:14474-14479 (1996).
242. J. A. Mennella and G. K. Beauchamp. The transfer of alcohol to human milk. Effects on flavor and the infant's behavior. N. Engl. J. Med. 325:981-985 (1991).
243. S. Bhattacharjee and P. Dasgupta. Molecular property correlation in alkanes with geometric volume. Comput. Chem. 18:61-71 (1994).
244. D. Gorse, A. Rees, M. Kaczorek, and R. Lahana. Molecular diversity and its analysis. Drug Discov. Today 4:257-264 (1999).
245. L. H. Hall and L. B. Kier. Design of molecules from quantitative structure-activity relationship models. 3. Role of higher order path counts path three. J. Chem. Inf. Comput. Sci. 33:598-603 (1993).
246. E. Estrada. Generalization of topological indices. Chem. Phys. Lett. 336:248-252 (2001).
247. M. J. Kogan, K. Verebey, and S. J. Mule. Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. Res. Commun. Chem. Pathol. Pharmacol. 18:29-34 (1977).
248. M. C. Meyer, A. B. Straughn, M. W. Lo, W. L. Schary, and C. C. Whitney. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J. Clin. Psych. 45:15-19 (1984).
249. J. V. Turner, D. J. Cutler, I. Spence, and D. J. Maddalena. Selective descriptor pruning for QSAR/QSPR studies using artificial neural networks. J. Comput. Chem. 24:891-897 (2003).